Open Label Phase 2 Study of the Safety and Biological Activity of GCS-100 in Subjects With Chronic Lymphocytic Leukemia.
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2013
At a glance
- Drugs GCS 100 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 25 Jan 2012 Status changed from suspended to discontinued.
- 20 May 2009 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
- 20 Oct 2008 Trial phase changed from I to II as reported by CT.gov